跳至主要内容
临床试验/EUCTR2009-015537-67-DE
EUCTR2009-015537-67-DE进行中(未招募)不适用

ntersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie

niversitätsmedizin der Johannes Gutenberg-Universität Mainz0 个研究点开始时间: 2009年10月26日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Alcohol dependent as defined by the criteria of Diagnostic and Statistical Manual of mental disorders (DSM IV)
  • Male and female in- or outpatients
  • Current smoker
  • Aged 18 to 65 years
  • Last consumption of alcohol 7-21 days before randomisation
  • Detoxified and free of withdrawal symptoms at randomisation
  • Sufficient knowledge of German language
  • Able to follow verbal and written instructions
  • Able to provide written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Delirium after current withdrawal, alcohol-induced dementia, Wernicke-Korsakoff syndrome
  • Severe renal insufficiency
  • Severe liver insufficiency
  • Involutary Detoxification
  • Female patients pregnant, breast feeding or fo child bearing age and not protected by medically acceptable contraception
  • Patients with clinically relevant concomitant psychiatric discorders (including a major depressive episode, psychotic discorders, antisocial personality disorder according to DSM IV in medial history)
  • Patients with an addiction or substance abuse of other addiction-inducing substances (except nicotine or cannabis) within the last 24 months before inclusion in the trial
  • Patient having a current suicide risk with a score > 6 at the suicidality item C of the M.I.N.I. international neuropsychiatric interview (MINI)
  • Patients with any clinically significant acute or chronic progressive neurological, gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, dermatological or respiratory disease
  • Patients with a current relevant depression (Hamilton Rating Scale for Depression (German version) values = 9 or Beck Depression Inventory (German version) values = 12)
  • Patients with a history of cancer within the last five years
  • Patients with a history of stroke or myocardial infarction within the last 6 months before screening

研究者

相似试验